<DOC>
	<DOCNO>NCT00990587</DOCNO>
	<brief_summary>This open-label , single arm study . Approximately 3-30 patient enrol . Patients receive Oral ciclopirox olamine ( aqueous suspension ) , initial start dose 5 mg/m2/day administer single dose daily 5 day . Three patient initially treat dose level sequential cohort . Dose escalation continue subsequent cohort base toxicity plasma drug concentration observe previous cohort . Dose escalation continue establishment maximum tolerate dose ( MTD ) meet . Patients demonstrated response treatment , 6 total cycle treatment may administer . If additional cycle warrant , ciclopirox olamine give dose frequency patient initially receive .</brief_summary>
	<brief_title>Study Evaluating Tolerance Biologic Activity Oral Ciclopirox Olamine Patients With Relapsed Refractory Hematologic Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Ciclopirox</mesh_term>
	<criteria>1 . Age &gt; 18 2 . Relapsed refractory hematologic malignancy include AML , ALL , CLL , high risk myelodysplasia ( International Prognostic Score &gt; 2.5 ) , CML blast crisis , multiple myeloma , nonHodgkin 's lymphoma , Hodgkin 's lymphoma potentially curative therapy option exhaust . 3 . ECOG ( Eastern Cooperative Oncology Group ) performance status &lt; 2 . 4 . Biochemical value within follow range : 1 . Serum creatinine &lt; 2x upper limit normal . 2 . Total bilirubin &lt; 2x upper limit normal , AST ( asparatate aminotransferase ) ALT ( alanine aminotransferase ) &lt; 5x upper limit normal . 5 . Ability maintain adequate oral intake medication . 6 . Ability understand sign inform consent . 7 . Toxicity prior chemotherapy resolve 1 . Uncontrolled systemic infection . 2 . Uncontrolled intercurrent illness 3 . Pregnant breast feed 4 . Active CNS ( central nervous system ) disease 5 . Neurologic symptom related intracurrent illness unexplained cause 6 . Psychiatric illness would limit compliance study 7 . Receiving systemic chemotherapy , hydroxyurea control circulate blast count , within 10 day study entry . Hydroxyurea permit , however dose must stable unchanged 7 day prior initiation ciclopirox olamine 8 . Concurrent therapy topical ciclopirox olamine . 9 . Use investigational anticancer therapy within two week study entry . 10 . Use oral intravenous metal supplement include iron , copper , zinc nickel . 11 . Resting ejection fraction &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>relapsed refractory hematologic malignancy</keyword>
	<keyword>ALL ( acute lymphoid leukemia )</keyword>
	<keyword>CLL ( chronic lymphoid leukemia )</keyword>
	<keyword>High risk myelodysplasia ( MDS ) IPSS ( International Prognostic Scoring System ) score &gt; 2.5</keyword>
	<keyword>CML ( chronic myelogenous leukemia ) blast crisis</keyword>
	<keyword>Relapsed refractory acute myeloid leukemia ( AML )</keyword>
</DOC>